Discriminant analyses of peanut allergy severity scores
Peanut allergy is one of the most prevalent food allergies. The possibility of a lethal accidental exposure and the persistence of the disease make it a public health problem. Evaluating the intensity of symptoms is accomplished with a double blind placebo-controlled food challenge (DBPCFC), which s...
Saved in:
Published in | Journal of applied statistics Vol. 38; no. 9; pp. 1783 - 1799 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Abingdon
Taylor & Francis
01.09.2011
Taylor and Francis Journals Taylor & Francis Ltd Taylor & Francis (Routledge) |
Series | Journal of Applied Statistics |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Peanut allergy is one of the most prevalent food allergies. The possibility of a lethal accidental exposure and the persistence of the disease make it a public health problem. Evaluating the intensity of symptoms is accomplished with a double blind placebo-controlled food challenge (DBPCFC), which scores the severity of reactions and measures the dose of peanut that elicits the first reaction. Since DBPCFC can result in life-threatening responses, we propose an alternate procedure with the long-term goal of replacing invasive allergy tests. Discriminant analyses of DBPCFC score, the eliciting dose and the first accidental exposure score were performed in 76 allergic patients using 6 immunoassays and 28 skin prick tests. A multiple factorial analysis was performed to assign equal weights to both groups of variables, and predictive models were built by cross-validation with linear discriminant analysis, k-nearest neighbours, classification and regression trees, penalized support vector machine, stepwise logistic regression and AdaBoost methods. We developed an algorithm for simultaneously clustering eliciting dose values and selecting discriminant variables. Our main conclusion is that antibody measurements offer information on the allergy severity, especially those directed against rAra-h1 and rAra-h3. Further independent validation of these results and the use of new predictors will help extend this study to clinical practices. |
---|---|
ISSN: | 0266-4763 1360-0532 |
DOI: | 10.1080/02664763.2010.529878 |